Prevalence and Severity of Drug Interactions in a Referral Pediatric Hospital: An Observational, Retrospective Study
,
Abstract
Background: Hospitalized infants and children are usually treated with many medications in the hospital. Concurrent use of multiple drugs, known as polypharmacy, is inevitable in critically ill patients. This study aims to investigate the possible interactions as well as their type and number, and their effect on the treatment process plus the duration of hospital stay of patients. Methods: In this descriptive study, the medical records of 189 patients admitted to the ICU ward of Mofid Children's Educational Hospital in Tehran were prospectively studied over six months. The collected data included disease diagnosis, patient medication information, age and gender, and treatment interventions. Interactions between drugs were identified using Up-to-date database, with the results analyzed by SPSS software. Results: The results revealed that hospitalization increased with an increasing number of drugs. The findings also indicated a direct relationship between the number of drug interactions and the duration of hospital stay. After examining the relationship between intensive care unit (ICU) outcome and the number of drug items as well as the number of drug interactions, it was found that there is a direct relationship between the two. There was also a direct relationship between Class D plus X interactions and mortality rate along with duration of stay. Conclusion: This study showed a direct relationship between drug interactions and the duration of hospitalization. In other words, as drug interactions increased, so did the duration of hospital stay.
2.Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals. Pediatr Crit Care Med. 2016;17(5):e218-28.
3.Yeh ML, Chang YJ, Yeh SJ, et al. Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants. Comput Methods Programs Biomed. 2014;113(1):15-22.
4.Hasnain H, Ali H, Zafar F, et al. Drug-drug interaction; facts and comparisons with national and international bentch marks. a threat more than a challenge for patient safety in clinical and economic scenario. The Professional Medical Journal. 2017;24:357-365.
5.Hassanzad M, Arenas-Lopez S, Baniasadi S. Potential Drug-Drug Interactions Among Critically Ill Pediatric Patients in a Tertiary Pulmonary Center. J Clin Pharmacol. 2018;58(2):221-227.
6.Ismail M, Aziz S, Noor S, et al. Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study. J Crit Care. 2017;40:243-250.
7.Rosen K, Wiesen MH, Oberthür A, et al. Drug-drug interactions in Neonatal Intensive Care Units: how to overcome a challenge. Minerva Pediatr (Torino). 2021;73(2):188-197.
8.Lima RE, De Bortoli Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222-7.
9.Gonçalves MG, Heineck I. Frequência de prescrições de medicamentos off label e não licenciados para pediatria na atenção primária à saúde em município do sul do Brasil [Frequency of prescriptions of off-label drugs and drugs not approved for pediatric use in primary health care in a southern municipality of Brazil]. Rev Paul Pediatr. 2016;34(1):11-7.
10.Pollack MM, Holubkov R, Reeder R, et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN). PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med. 2018;19(3):196-203.
11.Hammes JA, Pfuetzenreiter F, Silveira Fd, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Ter Intensiva. 2008;20(4):349-54.
12.Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009;35(4):603-12.
13.Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66(1):9-15.
14.Santibáñez C, Roque J, Morales G, Corrales R. Características de las interacciones farmacológicas en una unidad de cuidados intensivos de pediatría [Characteristics of drug interactions in a pediatric intensive care unit]. Rev Chil Pediatr. 2014;85(5):546-53. Spanish.
15.Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. Pediatrics. 2015;135(1):e99-108.
16.Fitzmaurice MG, Wong A, Akerberg H, et al. Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Drug Saf. 2019;42(9):1035-1044.
17.Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals. Pediatr Crit Care Med. 2016;17(5):e218-28.
18.Araujo TE, Vieira SM, Carvalho PR. Stress ulcer prophylaxis in pediatric intensive care units. J Pediatr (Rio J). 2010;86(6):525-30.
19.Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011;31(5):309-16.
20.Uijtendaal EV, van Harssel LL, Hugenholtz GW, et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213-9.
21.Camm AJ, Fox KAA. Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5(1):e000788.
| Files | ||
| Issue | Vol 10, No 3 (Summer 2022) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v10i3.10792 | |
| Keywords | ||
| Children Drug Interactions Intensive Care Unit | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
